(NASDAQ:CGEM), CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, […]

Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions GlobeNewswire October 25, 2025 NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still's disease across MAS subtypes, including in those with

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 GlobeNewswire October 25, 2025 CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc.

NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. ("Semler" or the "Company") (NASDAQ:SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

TheDigitalHotelier(TDH), the leading all-in-one platform for hospitality operational optimization, today announced its aggressive entry into the North American and Latin American (LATAM) markets. Headquartered in Dubai,TDH is solidifying its position as the dominant force in streamlining hotel operations, including housekeeping, staff training and management, and utility-cost mitigation through proactive alerts. https://mma.prnewswire.com/media/2805109/Ad_Image.jpg The key issue is

— Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation control — Sustained clinical response to stringent endpoints in half of patients with axial spondyloarthritis (nr-axSpA and AS):

NEW YORK CITY, NY / ACCESS Newswire / October 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or the "Company") (NYSE:NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail

NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) — Bittam Exchange, a rapidly emerging global cryptocurrency derivatives platform, today announced the launch of its New User Reward Program, offering traders up to $3,000 in bonuses as part of a broader initiative to expand fair, transparent, and high-performance trading access worldwide. The program coincides with Bittam's continued

(NASDAQ:KYTX), KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with observations from 100 patients treated with KYV-101 to date1 Emerging IIT data in RA reinforce broad potential for KYV-101 in rheumatology indications EMERYVILLE, Calif.,